Blepharospasm

Blepharospasm
Name	Blepharospasm
Field	Neurology, Ophthalmology
Symptoms	Involuntary eyelid closure, increased blinking, photophobia
Onset	Adult, often middle age
Causes	Idiopathic, secondary to neurological disease, medication-induced
Differential	Hemifacial spasm, myasthenia gravis, dry eye
Treatment	Botulinum toxin, surgery, medications, supportive therapy

Blepharospasm is a focal cranial dystonia characterized by involuntary, often forceful, spasms of the eyelid orbicularis oculi muscles leading to increased blinking and intermittent or sustained eyelid closure. It typically manifests in middle-aged adults and can progress from increased blink rate to functional visual impairment, with substantial impact on daily activities and quality of life. Patients may seek care from specialists in neurology, ophthalmology, or otolaryngology and may undergo multidisciplinary management involving movement disorder clinics and rehabilitation services.

Signs and symptoms

Patients present with involuntary eyelid contractions, frequent blinking, and episodes of sustained eyelid closure that can cause social embarrassment and functional blindness; these findings prompt referrals to clinics associated with Mayo Clinic, Cleveland Clinic, Johns Hopkins Hospital, Massachusetts General Hospital, and Charité – Universitätsmedizin Berlin. Associated features often include photophobia, increased ocular irritation, and use of sensory tricks such as touching the face or wearing tinted lenses; such behaviors are documented in case series from Harvard Medical School, University College London, University of California, San Francisco, Stanford University, and Columbia University. Comorbid movement disorders may coexist, including cranial dystonias or spreading dystonia noted in cohorts from National Institutes of Health, University of Toronto, Imperial College London, Karolinska Institute, and University of Oxford.

Causes and risk factors

Most cases are idiopathic, with epidemiologic associations reported by registries at Centers for Disease Control and Prevention, European Dystonia Federation, and academic centers such as University of Pennsylvania, Yale University, and University of Michigan. Secondary causes include medication-induced dystonia from dopamine antagonists and antiemetics implicated in studies at Mount Sinai Health System, Vanderbilt University Medical Center, and University of Chicago, as well as association with neurodegenerative conditions catalogued by World Health Organization collaborations and research from Mayo Clinic investigators. Risk factors described in case-control studies from Brigham and Women's Hospital, SUNY Downstate Medical Center, McGill University, Trinity College Dublin, and University of Sydney include female sex, middle age, family history of dystonia noted in pedigrees analyzed at University of Edinburgh, University of Groningen, and Heidelberg University.

Pathophysiology

Pathophysiologic models implicate dysfunction in basal ganglia circuits, brainstem interneurons, and cortical sensorimotor integration, with neuroimaging and electrophysiology data produced by teams at National Institute of Neurological Disorders and Stroke, Karolinska Institute, University College London, University of Toronto, and University of California, Los Angeles. Genetic investigations identifying risk loci and variants have been reported from consortia including researchers at Broad Institute, European Molecular Biology Laboratory, McGill University, University of Cambridge, and Cold Spring Harbor Laboratory. Altered inhibitory neurotransmission, including GABAergic and cholinergic pathways, has been explored in studies affiliated with Salk Institute, Vanderbilt University Medical Center, Johns Hopkins University School of Medicine, University of Pennsylvania Perelman School of Medicine, and Weill Cornell Medicine. Sensory trick phenomena and plasticity mechanisms are reported in basic science and clinical studies at Max Planck Society, Rikshospitalet–Radiumhospitalet, KU Leuven, University of Freiburg, and Seoul National University Hospital.

Diagnosis

Diagnosis is clinical, based on history and examination distinguishing it from hemifacial spasm, myasthenia gravis, and ocular surface disease; diagnostic pathways are outlined in guidelines from American Academy of Neurology, American Academy of Ophthalmology, European Academy of Neurology, Royal College of Ophthalmologists, and British Neuro-Ophthalmology Society. Ancillary testing may include electromyography, neuroimaging (MRI) to exclude structural lesions, and pharmacologic challenges discussed in protocols at Cleveland Clinic, Mayo Clinic, Johns Hopkins Hospital, Massachusetts Eye and Ear Infirmary, and University Hospitals Leuven. Standardized rating scales used in clinical trials and registries are developed by groups at Movement Disorder Society, European Dystonia Society, National Institute of Health Stroke Scale collaborators, National Eye Institute, and academic centers including University College London and University of California, San Francisco.

Treatment

First-line symptomatic therapy commonly involves local injections of botulinum neurotoxin administered by specialists trained at institutions such as Mayo Clinic, Cleveland Clinic, Johns Hopkins Hospital, Mount Sinai Health System, and Massachusetts General Hospital; formulations and dosing protocols are described in multicenter studies coordinated by Movement Disorder Society and International Parkinson and Movement Disorder Society. Surgical options, including myectomy of the orbicularis oculi, are performed in tertiary centers like Johns Hopkins Hospital, Mayo Clinic, UCLA Health, Royal Victoria Infirmary, and University Hospital Zurich for refractory cases. Oral medications such as anticholinergics, benzodiazepines, and baclofen are used adjunctively following trials at Stanford University, Vanderbilt University Medical Center, University of Toronto, Columbia University, and University of Melbourne. Rehabilitation approaches, botulinum toxin adjuncts, and investigational neuromodulation (deep brain stimulation targeting basal ganglia nuclei) have been evaluated in studies at University of Florida, Hartford Hospital, Mayo Clinic, Leiden University Medical Center, and Pitié-Salpêtrière Hospital.

Prognosis and complications

Prognosis varies: many patients achieve meaningful symptom control with botulinum toxin regimens coordinated through centers such as Mayo Clinic, Cleveland Clinic, Johns Hopkins Hospital, University College London Hospitals, and Karolinska University Hospital, while others experience progressive spread of dystonia reported by longitudinal cohorts at National Institute of Neurological Disorders and Stroke, European Dystonia Consortium, University of Oxford, McGill University, and University of Bonn. Complications include social withdrawal, depression, and occupational impairment documented in psychosocial research from Harvard Medical School, University of Pennsylvania, University of Sydney, Trinity College Dublin, and University of Toronto, as well as adverse effects of treatments such as ptosis or diplopia after injections reported in clinical series from Mayo Clinic, Cleveland Clinic, Johns Hopkins Hospital, UCLA Health, and Massachusetts General Hospital.

Category:Neurological disorders